ERBB2 and Thrombocytopenia: TPO-RA use is off-label for the purpose of therapy-induced thrombocytopenia as there is no FDA-approved indication; however, it has been shown to be well tolerated in the setting of chemotherapy-induced thrombocytopenia in individuals with solid tumor malignancies without an increased risk of thrombosis, which is the primary theoretical concern when utilizing these agents.9 Our results show that the concomitant use of TPO-RA can help maintain dose intensity and prolong the duration of therapy in individuals treated with these HER2-targeted ADC.